PRECISION ANTIBODY-BASED SYNERGISTIC DRUG COMBINATIONS FOR REFRACTORY TRIPLE-NEGATIVE BREAST CANCER

$1,714,270FY2021Defense Health AgencyDOD

The General Hospital Corporation

Investigators